title: Long-term benefits in lung function and nutritional status of strict metabolic control of cystic fibrosis-related diabetes.
abstract: Cystic fibrosis related diabetes (CFRD) is a strong determinant for lung function decline and increased mortality. Insulin treatment of CFRD is reportedly beneficial for this situation. We report on the long-term impact of insulin treatment of CFRD on pulmonary function and nutritional status in a CF male patient since diagnosis of diabetes. We report the case of a patient diagnosed with CF at the age of 16. Two years later, he experienced a rapidly evolving decrease in pulmonary function, some months later criteria were met warranting lung transplantation. Concomitantly, he was diagnosed with CFRD and insulin therapy was started. Lung function (spirometry), nutritional status (body mass index) and metabolic control (HbA(1c)) were determined every 3 months. After the introduction of insulin treatment, pulmonary function and nutritional status progressively improved and good glycemic control was achieved. The significant and sustained improvement in pulmonary function allowed for the patient's withdrawal from the lung transplantation program within 4 months, a situation which has been maintained until now, 8 years later. The long follow-up of our patient documents the rapid and prolonged beneficial effect of proper metabolic control of CFRD on the respiratory deterioration in CF.
authors.affiliation: Unidad de Diabetes Pediátrica, Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, España. mmartinf.hrc@salud.madrid.org
authors.forename: María
authors.initials: M
authors.lastname: Martín-Frías
authors.forename: Luis
authors.initials: L
authors.lastname: Máiz
authors.forename: Atilano
authors.initials: A
authors.lastname: Carcavilla
authors.forename: Raquel
authors.initials: R
authors.lastname: Barrio
mesh_terms: D000293:Adolescent; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D009752:Nutritional Status; D013147:Spirometry; D013997:Time Factors
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human